Platelets Impair Inflammation Resolution in Atherosclerosis During Lipid-Lowering Treatment

Strategic Insights -

Researchers from the New York University Grossman School of Medicine have discovered that platelets hinder the resolution of inflammation in atherosclerotic plaques in insulin-resistant mice after lipid-lowering treatment. This finding suggests that platelets impair the benefits of lipid-lowering treatment in individuals with type 2 diabetes, leading to a higher cardiovascular risk. The study's results also showed that targeting platelets with novel therapies may be a promising approach to promote atherosclerotic plaque inflammation-resolution.

Key Takeaways:

  • Platelets impair the resolution of inflammation in atherosclerotic plaques in insulin-resistant mice after lipid-lowering treatment.
  • Insulin resistance impairs the benefits of lipid-lowering treatment, leading to a higher cardiovascular risk in individuals with type 2 diabetes.
  • Targeting platelets with novel therapies may be a promising approach to promote atherosclerotic plaque inflammation-resolution.
  • The study's results suggest that platelet-depleting antibodies can reduce plaque macrophages and inflammation, while increasing collagen content and reducing necrotic core size.
  • Clinical data showed that patients with lower platelet counts had decreased pro-inflammatory signaling pathways in circulating non-classical monocytes after lipid-lowering.
  • The research identified a subset of Fcgr4+ macrophages with features of inflammation-resolving, phagocytic cells in platelet-depleted mice.
  • The findings highlight the potential of platelet-targeted therapies in promoting atherosclerotic plaque inflammation-resolution.

Statistics:

  • 3 weeks: duration of platelet-depleting or control antibody treatment in mice.
  • 75: page number of the Obesity & Diabetes Week report.
  • 2025: year of publication of the research in Jci Insight.
  • 2015 Manchester Rd, Ann Arbor, MI 48104, USA: address of the Amer Soc Clinical Investigation Inc.
  • 25: Age of mice used in the study.
  • 10-15%: proportion of Fcgr4+ macrophages in platelet-depleted mice.

Sources:

  • Jci Insight. (2025). Platelets impair the resolution of inflammation in atherosclerotic plaques in insulin-resistant mice after lipid-lowering. Amer Soc Clinical Investigation Inc, 2015 Manchester Rd, Ann Arbor, MI 48104, USA.
  • Obesity & Diabetes Week. (October 20, 2025; p 75). New Insulin Resistance Study Findings Have Been Reported by Researchers at New York University Grossman School of Medicine (Platelets impair the resolution of inflammation in atherosclerotic plaques in insulin-resistant mice after lipid-lowering).
  • NewsRx. (2025). New Insulin Resistance Study Findings Have Been Reported by Researchers at New York University Grossman School of Medicine (Platelets impair the resolution of inflammation in atherosclerotic plaques in insulin-resistant mice after lipid-lowering).